Background Multiple long-term conditions (MLTCs) are common among individuals with heart failure (HF); however, the influence ...
Omeros to Host Conference Call Monday, December 29, 2025 at 4:30 p.m. ET -- -- First and only approved option: YARTEMLEA(R) is the only approved treatment for hematopoietic stem cell ...
Objectives To date, consistent evidence for consequences of heading in football (soccer) on the structure and function of the ...
Hematologists and oncologists from UC San Francisco shared research results and clinical guidance at the world’s premier meeting for malignant and non-malignant hematology at the American Society of ...
An agentic AI-based approach to end-to-end bug resolution using both error logs and waveforms.
Findings from the phase 1/2 BRUIN study (NCT03740529) show that pirtobrutinib (Jaypirca), a Bruton tyrosine kinase inhibitor (BTKi), monotherapy offers promising clinical efficacy and a favorable ...
At the recent American Society of Hematology annual meeting, real-world analyses examined how polatuzumab vedotin (Polivy) ...
Key Takeaways. TTP following R-CHOP is a strong prognostic factor for survival in R/R DLBCL, with shorter TTP linked to ...
Scientific studies claim that modern music has become simpler than ever before, both lyrically and musically. But are they ...
An analysis of Tesla’s patent applications shows a slower pace of innovation in the last 2 years and a shift toward AI ...
The waveLINE-003 trial demonstrates the efficacy of zilovertamab vedotin combined with standard therapy, with manageable safety profiles in difficult-to-treat DLBCL patients. ADCs provide logistical ...
Researchers have shown that glioblastoma can take over the skull marrow to dissolve bone and feed its own growth, suggesting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback